Daré Bioscience (NASDAQ:DARE) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Shares of Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.33 and traded as low as $2.88. Daré Bioscience shares last traded at $2.88, with a volume of 15,094 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Trading Down 1.4 %

The firm has a market cap of $25.06 million, a P/E ratio of -4.88 and a beta of 1.38. The business has a 50-day moving average of $3.15 and a two-hundred day moving average of $3.33.

Institutional Investors Weigh In On Daré Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of DARE. Geode Capital Management LLC grew its position in shares of Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Daré Bioscience in the 4th quarter valued at about $52,000. Finally, AMH Equity Ltd grew its position in shares of Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 50,000 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.